Search

Este artigo traz um relato de experiência do ensino de informática básica e robótica para Pessoas com Deficiência Intelectual e Múltipla atendidas pela Associação de Pais e Amigos dos Excepcionais do município de Serra Talhada-PE. O objetivo deste trabalho é apresentar um currículo base de informática e robótica, assim como sua aplicação nas oficinas que são realizadas semanalmente no laboratório de informática da associação. O currículo se mostrou adequado para PcD, aprimorando suas habilidades e promovendo a inclusão sociodigital.

Nanocarriers have gained enormous highlight as a platform for drug delivery. These systems are often prepared with a variety of either natural or synthetic lipid, polymeric and inorganic materials. Preparation protocols include different bottom-up and top-down strategies, depending on the physicochemical characteristics of the raw materials and drugs. Moreover, the physicochemical properties of nanocarriers can be investigated with different analytical techniques, including dynamic light scattering, electron microscopy, differential scanning calorimetry, etc. The great interest for these nanocarriers is owing to their advantages for drug delivery, such as the protection of the encapsulated drug against degradation, the possibility of sustained release, higher solubility of lipophilic drugs, improved pharmacokinetics, prolonged circulation, passive targeting to solid tumors, based on the enhanced permeability and retention (EPR) effect. Also, these nanocarriers can be actively targeted to disease sites through functionalization using moieties such as peptides, folate, monoclonal antibodies and others. Altogether, these characteristics lead to improved efficacy of drugs in the treatment of a variety of diseases, with reduced side effects. Furthermore, nanocarriers have been successfully demonstrated as effective for diagnosis of diseases and have been also employed as theranostic agents. The application of nanocarriers for both treatment and diagnosis of diseases has been thoroughly investigated both in vitro, in cell culture experiments and in vivo, using xenograft animal models, for cancer, for example. However, nanocarriers are promising for application in other conditions, including inflammatory, infectious and degenerative diseases. Finally, many clinical trials have confirmed the efficacy and safety of nanocarriers, and nowadays, there is a variety of formulations available in the market, particularly liposomes. In the next years, many more nanocarriers are expected to move from bench to bedside, particularly in the field of cancer therapy.

Made available in DSpace on 2020-12-12T02:11:22Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-10-01 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Prostate cancer is the second cause of cancer death in men worldwide. Docetaxel (DTX), an antimitotic drug, is widely used for the treatment of metastatic prostate cancer patients. Taxotere® is a commercial DTX formulation. It contains a polysorbate 80 surfactant to improve DTX aqueous solubility, which has been associated with hypersensitivity reactions in patients. Liposomes have been used as promising delivery systems for a range of hydrophobic drugs, such as DTX, offering improved drug water solubility and biocompatibility, without compromising its anticancer activity. Herein, DTX-loaded liposomes were developed using the Box-Behnken factorial design. The optimized formulation was nano-sized, homogenous in size (67.47 nm) with high DTX encapsulation efficiency (99.95 %). The encapsulated DTX was in a soluble amorphous state, which was slowly released. Next, to increase the liposomes selectivity to prostate cancer cells, cetuximab, an anti-EGFR monoclonal antibody. was successfully conjugated to the surface of liposomes, without compromising cetuximab protein structure and stability. As expected, our results showed higher cellular uptake and toxicity of immunoliposomes, compared to non-targeted liposomes, in DU145 (EGFR-overxpressing) prostate cancer cells. To the best of our knowledge, this is the first report of engineering EGFR-targeted liposomes to enhance the selectivity of DTX delivery to EGFR-positive prostate cancer cells. Federal University of Ceará College of Pharmacy Dentistry and Nursing Department of Pharmacy School of Pharmacy Queen's University Belfast, 97 Lisburn Rd School of Pharmaceutical Sciences of Araraquara São Paulo State University UNESP Department of Drugs and Medicines University for International Integration of the Afro-Brazilian Lusophony Institute of Health Sciences College of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo São Carlos Institute of Chemistry University of São Paulo School of Pharmaceutical Sciences of Araraquara São Paulo State University UNESP Department of Drugs and Medicines

Summary Cardiovascular diseases are among the main causes of mortality worldwide, and dyslipidemia is a principal factor risk. Hence the study of biochemical markers is necessary for early diagnosis. Objectives Evaluate biomarkers to diagnose the risks of cardiovascular diseases in healthy Brazilian and African young adults. Design & Methods Weight, height, waist circumference, percentage of body fat and systemic blood pressure were measured; and fasting blood samples were taken for biochemical analysis. Triglycerides, total cholesterol, HDL-c, and apolipoproteins A-I and B were measured on automated equipment using commercially available kits, in addition to the tests of antioxidant capacity of HDL and the enzymatic activity of Paraoxonase 1. Results After statistical analysis, it was found that BMI, WC, fat (%), triglycerides, ApoB/ApoA-I ratio and Vmax were higher in Brazilians, while HDL-c, ApoA-I, Lag Time, Vmax and PON1 activity were higher in Africans. In Brazilians, the ApoB/ApoA-I ratio was related to obesity factors and lipid profile, but in Africans it was related only to lipids. The antioxidant capacity of HDL and PON1 activity was better in Africans. Through independence testing, we observed an association with moderate risk of myocardial infarction with gender in Africans. In the binary logistic regression analysis, it was found that men in general – and particularly African men – have higher risk of myocardial infarction than women; Odds Ratio 2144 (CI95%: 1343–3424) and 2281 (CI95%: 1082–4811), respectively. Conclusions The anthropometric and biochemical parameters of Brazilians, especially men, predispose them to greater risks of cardiovascular diseases.

The epidermal growth factor receptor (EGFR) belongs to the tyrosine kinase receptors family and is present in the epithelial cell membrane. Its endogenous activation occurs through the binding of different endogenous ligands, including the epidermal growth factor (EGF), leading to signaling cascades able to maintain normal cellular functions. Although involved in the development and maintenance of tissues in normal conditions, when EGFR is overexpressed, it stimulates the growth and progression of tumors, resulting in angiogenesis, invasion and metastasis, through some main cascades such as Ras/Raf/MAPK, PIK-3/AKT, PLC-PKC and STAT. Besides, considering the limitations of conventional chemotherapy that result in high toxicity and low tumor specificity, EGFR is currently considered an important target. As a result, several monoclonal antibodies are currently approved for use in cancer treatment, such as cetuximab (CTX), panitumumab, nimotuzumab, necitumumab and others are in clinical trials. Aiming to combine the chemotherapeutic agent toxicity and specific targeting to EGFR overexpressing tumor tissues, two main strategies will be discussed in this review: antibody-drug conjugates (ADCs) and antibody-nanoparticle conjugates (ANCs). Briefly, ADCs consist of antibodies covalently linked through a spacer to the cytotoxic drug. Upon administration, binding to EGFR and endocytosis, ADCs suffer chemical and enzymatic reactions leading to the release and accumulation of the drug. Instead, ANCs consist of nanotechnology-based formulations, such as lipid, polymeric and inorganic nanoparticles able to protect the drug against inactivation, allowing controlled release and also passive accumulation in tumor tissues by the enhanced permeability and retention effect (EPR). Furthermore, ANCs undergo active targeting through EGFR receptor-mediated endocytosis, leading to the formation of lysosomes and drug release into the cytosol. Herein, we will present and discuss some important aspects regarding EGFR structure, its role on internal signaling pathways and downregulation aspects. Then, considering that EGFR is a potential therapeutic target for cancer therapy, the monoclonal antibodies able to target this receptor will be presented and discussed. Finally, ADCs and ANCs state of the art will be reviewed and recent studies and clinical progresses will be highlighted. To the best of our knowledge, this is the first review paper to address specifically the EGFR target and its application on ADCs and ANCs.